Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9$110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million,$0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million,$1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 2024 Total ...